Literature DB >> 1913683

Frequent induction of mammary carcinomas following neu oncogene transfer into in situ mammary epithelial cells of susceptible and resistant rat strains.

B Wang1, W S Kennan, J Yasukawa-Barnes, M J Lindstrom, M N Gould.   

Abstract

Varying results have been reported on the role of neu oncogene in mammary carcinogenesis. In order to further address this issue, the activated neu oncogene was introduced into mammary epithelial cells in situ of both mammary carcinoma-susceptible Wistar Furth and resistant Copenhagen rats by infusing replication-defective recombinant retroviruses carrying the neu oncogene into the mammary gland lumen. At the highest virus titer tested, very high numbers of mammary carcinomas developed within 2 weeks in all exposed glands in both rat strains. When the virus titer was reduced, however, individual tumors occurred with varying latencies. In addition, not all of the neu-infected mammary cells progressed to form mammary carcinomas. These results suggest that while neu is a potent mammary transforming gene, either other events in addition to neu expression may be required for full malignant transformation or not all mammary ductal epithelial cells are able to be neoplastically transformed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1913683

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Mcs5c: a mammary carcinoma susceptibility locus located in a gene desert that associates with tenascin C expression.

Authors:  Adeline L Veillet; Jill D Haag; Jane L Remfert; Amanda L Meilahn; David J Samuelson; Michael N Gould
Journal:  Cancer Prev Res (Phila)       Date:  2011-01

2.  Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer.

Authors:  M J Hoenerhoff; M A Shibata; A Bode; J E Green
Journal:  Transgenic Res       Date:  2010-06-12       Impact factor: 2.788

3.  Tamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model.

Authors:  Norman C Peterson; Matthew D Servinsky; Archie Christian; Zhongsheng Peng; Weiping Qiu; Jill Mann; John Dicello; David L Huso
Journal:  Carcinogenesis       Date:  2005-04-28       Impact factor: 4.944

Review 4.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

Review 5.  Rat models of premalignant breast disease.

Authors:  H J Thompson; M Singh
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

6.  Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors.

Authors:  P M Siegel; D L Dankort; W R Hardy; W J Muller
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

7.  A short-term rat mammary carcinogenesis model for the prevention of hormonally responsive and nonresponsive in situ carcinomas.

Authors:  Stephan Woditschka; Jill D Haag; Ruth Sullivan; Michael N Gould
Journal:  Cancer Prev Res (Phila)       Date:  2009-02

8.  Freund's vaccine adjuvant promotes Her2/neu breast cancer.

Authors:  Michelle S Cotroneo; Jill D Haag; Nicholas R Stapel; Jordy L Waller; Stephan Woditschka; Michael N Gould
Journal:  BMC Cancer       Date:  2009-01-14       Impact factor: 4.430

9.  Chemopreventive effects of celecoxib are limited to hormonally responsive mammary carcinomas in the neu-induced retroviral rat model.

Authors:  Stephan Woditschka; Jill D Haag; Bob Mau; Ronald A Lubet; Michael N Gould
Journal:  Breast Cancer Res       Date:  2008-02-15       Impact factor: 6.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.